The University of Minnesota Eastern Cooperative Oncology Group (ECOG) Program is a multimodality research activity. It is clear that multidisciplinary programs are the best equipped to develop and evaluate treatments and concepts in cancer research at the cooperative group level. Our program includes radiotherapists, medical oncologists, surgeons, immunologists, clinical pharmacologists and pathologists in a coordinated effort to improve evaluation and treatment of cancer patients. We continue to maintain a sound accrual record with a full range of ECOG protocols. Our program has a strong leadership role within ECOG, with members serving on the ECOG Executive Committee, as well as the Breast, Head and Neck, GI, Hematology, Data Management, Radiation Therapy, Surgery and cancer Control Steering Committees. Minnesota investigators chair or co-chair the Ethics Review Committee, as well as the Toxicity and Response, Head and Neck and Hematology Committees. During the grant period, University of Minnesota investigators have chaired or co-chaired 23 ECOG protocols and have published over 30 papers and abstracts reporting ECOG studies. This scientific productivity has proceeded at an accelerating rate, and includes ample evidence of the responsiveness of this Program to new initiatives such as epidemiologic studies, work with biologic response modifiers, radiosensitizers and bone marrow transplantation, full participation in the audit program of ECOG and the productive affiliation of the West Metro Minneapolis CCOP program into the U of M ECOG Program. Our Program is well equipped to participate in ECOG activities because of its sound organizational stability and its committed multidisciplinary group of investigators with the ready availability of specialized diagnostic and therapeutic procedures and subspecialty support in all relevant clinical areas. A vigorous ECOG program is essential to the effective utilization of the extensive patient resources in this area for cooperative group studies. The University of Minnesota ECOG Program has matured since its initial funding in 1978 to become one of the leading cooperative group programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA020365-08
Application #
3556516
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-06-01
Project End
1989-04-30
Budget Start
1985-06-01
Budget End
1986-04-30
Support Year
8
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
Schools of Medicine
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Forastiere, A A; Leong, T; Rowinsky, E et al. (2001) Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 19:1088-95
Harris, J E; Ryan, L; Hoover Jr, H C et al. (2000) Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 18:148-57
Oken, M M; Leong, T; Lenhard Jr, R E et al. (1999) The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer 86:957-68
Wiernik, P H; Phillips, V; Camacho, F J et al. (1998) Methylguazone, vindesine and cisplatin for the treatment of patients with relapsed or refractory malignant lymphoma: an Eastern Cooperative Oncology Group Study (PA482). Leuk Lymphoma 30:619-24
Paietta, E; Van Ness, B; Bennett, J et al. (1992) Lymphoid lineage-associated features in acute myeloid leukaemia: phenotypic and genotypic correlations. Br J Haematol 82:324-31
Weisdorf, D J; Andersen, J W; Glick, J H et al. (1992) Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. J Clin Oncol 10:942-7
Paietta, E; Van Ness, B; Le Beau, M M et al. (1992) Translocation (2;9)(p12;p23) in a case of acute leukemia with t(4;11)(q21;q23). Lack of rearrangement of the kappa and interferon gene loci. Cancer Genet Cytogenet 60:82-5
Paietta, E; Van Ness, B; Bennett, J M et al. (1991) Unexpected immunoglobulin light chain gene rearrangements in myeloid antigen positive acute lymphoid leukemia. Leuk Res 15:149-55
Tormey, D C; Gray, R; Gilchrist, K et al. (1990) Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. Cancer 65:200-6
Feddersen, R M; Martin, D J; Van Ness, B G (1990) The frequency of multiple recombination events occurring at the human Ig kappa L chain locus. J Immunol 144:1088-93

Showing the most recent 10 out of 15 publications